China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot firm China Resource Medicine Commercial Holdings Ltd. The partnership aims to expand market reach, enhance promotion efforts, and boost sales. Financial details of the agreement were not disclosed.
Hybio Pharma’s Strategic Leverage
Hybio Pharma, a key long-term partner of CR Medicine, plans to utilize its robust product pipeline in conjunction with CR Medicine’s extensive marketing channels and customer resources. This strategic move is designed to accelerate product innovation, particularly in the cardiovascular disease field, where Hybio Pharma has a strong focus.
CR Medicine’s Distribution Capabilities
CR Medicine, a prominent pharmaceutical distributor and a wholly-owned subsidiary of CR Pharma, is well-equipped to handle drug and device import and export operations as well as third-party pharmaceutical distribution. This capability will be instrumental in supporting Hybio Pharma’s market expansion efforts.
Hybio’s Diverse Product Pipeline
Hybio is a peptide drug developer with a diverse portfolio. Its product pipeline includes innovative offerings such as the HY3000 nasal spray and HY3001 polypeptide vaccine. In the realm of hypoglycemic and weight-loss products, Hybio offers liraglutide, semaglutide, and exenatide. The company also provides a range of gynecological auxiliary reproductive products, including atosiban, carbetocin, cetrorelix, and ganirelix. Additionally, Hybio’s osteoporosis treatment products encompass salmon calcitonin, teriparatide, abaloparatide, and others, showcasing its commitment to addressing various therapeutic areas.-Fineline Info & Tech
